MA44323A - Nanosphères à surface modifiée encapsulant des molécules liant l'antigène - Google Patents

Nanosphères à surface modifiée encapsulant des molécules liant l'antigène

Info

Publication number
MA44323A
MA44323A MA044323A MA44323A MA44323A MA 44323 A MA44323 A MA 44323A MA 044323 A MA044323 A MA 044323A MA 44323 A MA44323 A MA 44323A MA 44323 A MA44323 A MA 44323A
Authority
MA
Morocco
Prior art keywords
binding molecules
antigen binding
surface modified
nanospheres
nanospheres encapsulating
Prior art date
Application number
MA044323A
Other languages
English (en)
Inventor
Anamarija Curic
Christopher Untucht
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of MA44323A publication Critical patent/MA44323A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des nanosphères qui comprennent une matrice polymère et des molécules de liaison à l'antigène estérase incorporées de manière amovible dans celle-ci et qui sont recouvertes de molécules de ciblage qui augmentent l'absorption cellulaire des nanosphères. La matrice polymère est formée de poly (alkyl cyanoacrylates) et / ou de leurs dérivés alcoxy. L'invention concerne en outre des procédés de préparation et des compositions comprenant de telles nanosphères.
MA044323A 2015-11-20 2016-11-17 Nanosphères à surface modifiée encapsulant des molécules liant l'antigène MA44323A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562258077P 2015-11-20 2015-11-20

Publications (1)

Publication Number Publication Date
MA44323A true MA44323A (fr) 2018-09-26

Family

ID=57485443

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044323A MA44323A (fr) 2015-11-20 2016-11-17 Nanosphères à surface modifiée encapsulant des molécules liant l'antigène

Country Status (4)

Country Link
US (1) US20190254983A1 (fr)
EP (1) EP3377115A2 (fr)
MA (1) MA44323A (fr)
WO (1) WO2017085212A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3678706A1 (fr) 2017-09-07 2020-07-15 Abbvie Deutschland GmbH & Co. KG Nanoparticules modifiées par l'albumine portant un ligand de ciblage
EP3952836A1 (fr) * 2019-04-10 2022-02-16 Sintef Tto As Nanoparticules comprenant des composés copolymères ou homopolymères qui comprennent des sous-unités de cyanoacrylate
EP4584011A1 (fr) * 2022-09-08 2025-07-16 Evonik Operations GmbH Fabrication améliorée de nanovecteur
CN116813458B (zh) * 2023-06-26 2024-06-14 广东省科学院生物与医学工程研究所 一种提高牛血清白蛋白共聚物负载性能的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000514440A (ja) * 1996-07-09 2000-10-31 ザ ジョーンズ ホプキンス ユニバーシティー 遺伝子輸送システム
EP1815851A1 (fr) 2006-02-03 2007-08-08 NanoDel Technologies GmbH Nanoparticules pour l'administration de médicaments
WO2009135854A2 (fr) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation d’agents biologiquement actifs
JP2011519894A (ja) * 2008-05-06 2011-07-14 グラクソ グループ リミテッド 生物活性薬の封入
WO2015181344A1 (fr) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation de molécules de liaison à l'antigène

Also Published As

Publication number Publication date
WO2017085212A3 (fr) 2017-06-29
EP3377115A2 (fr) 2018-09-26
WO2017085212A2 (fr) 2017-05-26
US20190254983A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
MA44323A (fr) Nanosphères à surface modifiée encapsulant des molécules liant l'antigène
MA31496B1 (fr) Inhibiteurs macrocycliques innovants de la replication du virus de l'hepatite c
MA31497B1 (fr) Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c
MA38567A1 (fr) Variantes de pertuzumab et leur évaluation
MA52742B1 (fr) Anticorps bispécifiques dll3-cd3
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
FR2964385B1 (fr) Charges modifiees et composites elastomeres les comprenant
EP4242655A3 (fr) Procédés et compositions pour le traitement du cancer et d'infections pérsistantes en inhibant la voie de la mort céllulaire programmée (pd-1)
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
EA201990297A1 (ru) Лист стекла, приближающийся по своим характеристикам к нейтральному независимо от толщины
EA201990105A1 (ru) Листовое стекло, пригодное для химической закалки
DE602006010564D1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
EA201001639A1 (ru) Композиции и способы их получения и применения
MA33541B1 (fr) Nouvelles compositions biopesticides et leur procédé d'isolement et de caractérisation
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MA34590B1 (fr) Compositions pesticides
MA31605B1 (fr) Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
MA32225B1 (fr) Nouveaux inhibiteurs macrocycliques de la replication du virus de l'hepatite c
MA35880B1 (fr) Composition à base d'acariens comprenant un acarien prédateur et une proie immobilisée en contact avec un agent réduisant les champignons, et procédés et utilisations associés à l'utilisation de ladite composition
MA32360B1 (fr) Thérapie pour cancer hépatique
GEP20135929B (en) Compositions containing asphalt
MA38371A1 (fr) Matériau hybride organique-inorganique, utile pour extraire l'uranium(vi) de milieux aqueux comprenant de l'acide phosphorique, ses procédés de préparation et ses utilisations
EA200500074A1 (ru) Пленочное покрытие для таблеток и каплет
EA202192646A1 (ru) Лиофилизированная композиция, содержащая соединение бензоазепина